Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer Care Visiting Professorship Program

Organization
Prostate Cancer Foundation (PCF) and Pfizer Inc.
Type
Industry
Application Due Date
06-26-2026
Comments
Grant Application due June 23, 2026. Please note the deadline is 23:59 Eastern Time (New York, GMT -5). Applications submitted after deadline will not be reviewed.
Brief Description

About this Visiting Professorship (VP) Program 

This RFP is to provide financial support to community-based urology and medical oncology Organizations (e.g., independent community urology practices governed by a Board of Directors, community-based medical oncology groups, hospital-affiliated community cancer centers) to host and coordinate a 2.5-to-3 hour medical education program to be led by 1-2 Visiting Professors whose expertise matches the Organization’s unmet educational and practice needs related to germline/genetic and somatic (tumor and/or ctDNA) testing for patients with prostate cancer, such as: 

  • Understanding the science of these tests and clinical applications of testing
  • Patient selection (whom to test and when)
  • Communicating benefits of testing, risks and results and implications to patients and families
  • Effective strategies to integrate testing into clinical workflows, such as enabling advanced practice providers to provide support and/or incorporating novel digital tools that support clinical decision-making
  • Addressing and overcoming financial and reimbursement barriers to testing

Targeting these gaps, the goals of this first-time competitive Visiting Professor program are to provide meaningful education for prostate cancer care teams in community practice, building capacity by helping them identify gaps in patient care, helping engineer practice-level solutions, and fostering collaborations among community-based practitioners and academic experts. Urologists, medical oncologists, advanced practice providers, and patients will benefit from the knowledge and onsite presence of distinguished clinical experts who might otherwise be inaccessible.

The goal of this program is to help initiate/ implement a practice level-solution to improve the delivery of prostate cancer care at the grantee’s site specific to their unique practice gaps related to germline and somatic testing. Our support for this program reflects our commitment to improving outcomes for patients with prostate cancer and advancing clinical expertise, education, and capacity for healthcare professionals.